https://health.economictimes.indiatimes.com/news/pharma/glenmark-to-launch-higher-strength-of-fabiflu-for-mild-and-moderate-symptoms-of-covid-19/77393737
Glenmark to launch higher strength of FabiFlu for mild and moderate symptoms of Covid-19,...
FabiFlu: The higher strength will improve compliance for patients by effectively reducing the number of tablets required per day, Glenmark said in a statement.
https://www.indiatvnews.com/business/news-fabiflu-tablets-dosage-covid-19-treatment-favipiravir-glenmark-indian-company-gets-approval-628184
Glenmark says FabiFlu reduces viral load by 4 days, treats mild to moderate COVID-19 | Business...
Jun 22, 2020 - Glenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to...